Who we are
Smith+Nephew is a portfolio medical technology company focused on the repair, regeneration and replacement of soft and hard tissue.
Smith+Nephew is a portfolio medical technology company focused on the repair, regeneration and replacement of soft and hard tissue.
Visit our investor section to find information about financial performance, information for private shareholders, investor presentations and annual reports.
We have a history dating back over 160 years.
1856
Thomas James Smith opened a chemist shop in Hull, UK and develops a new method for refining cod liver oil.
1896
Horatio Smith entered a partnership with his uncle forming TJ Smith & Nephew.
1906
Anticipating the decline of his cod liver oil business, H N Smith buys a bandage cutting and rolling machine, turning the focus of the business to the sale of wound dressings and bandages.
H N Smith travels to North America and secures contracts to supply Canadian hospitals with bandages.
1907
Smith & Nephew becomes a limited company.
1914
Days after the declaration of World War 1 in 1914, Horatio Nelson Smith (the nephew of the company founder T. J Smith) met with an envoy of the French President in London. The company was awarded a contract to supply £350,000 of surgical and field dressings, to be delivered in five months.
During WW1, staff grew from 50 to 1,200.
1921
The first independent overseas branch of Smith & Nephew opens in Canada.
1928
We produced our experimental bandage ElastoplastTM
1937
We were listed on the London Stock Exchange.
We developed a special low-temperature plaster, used by the Everest climbers on the 1953 expedition. It enabled them to send back camera films, sealed and airtight!
Post war expansion
1950s
New companies are formed in Australia (1950) and New Zealand (1953).
1951
Smith & Nephew acquires Herts Pharmaceuticals, introducing pharmaceutical and skincare products to the Group, as well as laboratory and technical resources, enabling the company to forge ahead with its programmes of product research and development.
1986
We made two key acquisitions:
1995
We acquired Acufex Microsurgical Inc., making us a market leader in arthroscopic surgical devices.
We were listed on the New York Stock Exchange.
2001
We became a constituent member of the UK FTSE 100 Index.
We introduced OXINIUM◊, a new material that improves performance and increases the service life of total joint replacement systems.
2011
PICO◊ the first pocket-sized, single-use system, revolutionizes the negative pressure wound therapy market.
2013
JOURNEY II◊ BCS sets a new standard in knee implant performance, designed to empower patients.
2014
Acquired Arthrocare Corp. to expand our sports medicine portfolio.
2015
Acquired Blue Belt Technologies, securing a leading position in orthopaedic robotics-assisted surgery.
2019
Expanding in technologies of the future, we acquired: Osiris Therapeutics, Ceterix Orthopaedics, Leaf Patient Monitoring System and Brainlab Orthopaedic Joint Reconstruction Business.
2020
Launched Real Intelligence and CORI◊ Surgical System, our next-generation handheld robotics platform.
2021
Acquired the orthopaedic extremity business from Integra, strengthening our position in a high-growth segment.
Today
We have over 18,000 employees worldwide and we operate in over 100 countries.
We are committed to the highest standards of corporate governance.
Find out more about our Board of Directors and Leadership team.